obesity » Trang Công Nghệ | Trangcongnghe.vn

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Globe Newswire

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Globenewswire -

Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic health

Globe Newswire

Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic health

Globenewswire -

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Globe Newswire

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Globenewswire -

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Globe Newswire

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Globenewswire -

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Globe Newswire

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Globenewswire -

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

Globe Newswire

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

Globenewswire -

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Globe Newswire

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Globenewswire -

XEM THÊM TIN MỚI